LEWISTON, N.Y., March 30 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it received a regulatory approval to market and sell its patented and proprietary LAM IPM Wound Gel(TM) in Ecuador. The approval was granted by the Instituto Nacional de Higiene y Medicina Tropical Leopoldo Izquieta Perez (the Ecuadorian Ministry of Health), approval number "26291-03-05." As previously stated, a series of official launch presentations for the wound gel are scheduled for the week of April 18, 2005 in Ecuador.
Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals Inc., LAM's distribution partner for Ecuador, stated, "The approval for LAM IPM Wound Gel(TM) coincides with our pre-launch initiatives. We are now in an excellent position to fully capitalize on the favorable results being achieved with the Gel in the various hospital studies."
Mr. Diego Pesatnez, General Manager of aQva Pharmaceuticals Inc in Ecuador, added, "We have been conducting extensive groundwork in anticipation of the approval for the LAM IPM Wound Gel(TM). We are delighted to have the official registration number in our hands. We can now further accelerate all our commercial initiatives and look forward to a successful launch in April."
Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, noted, "We would like to thank our partners at aQva for their efforts in obtaining the approval and developing a comprehensive launch program for the Gel. We look forward to continuing to work with aQva as we complete product commercialization in Ecuador, including the inclusion of the LAM IPM Wound Gel(TM) on Ecuador national government formulary."
About LAM Pharmaceutical, Corp.
L.A.M. Pharmaceutical, Corp., http://www.lampharm.com/, is a biomedical company with offices in Lewiston, New York, Toronto, Canada and Beijing, China. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.
About aQva Pharmaceuticals
aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Stephanie Carrington (Investors/Media)
The Ruth Group
LAM Pharmaceutical, Corp.